Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
One experimental injection helped mice and pigs heal after heart attack by boosting a protective heart hormone. (CREDIT: ...
Proper pullet vaccination underpins the protection of layers and broiler breeders during the rearing phase. When done correctly, it stabilises egg ...
RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies, today announced that portfolio company SteerBio, a biotech ...
The global healthcare landscape is witnessing a transformative shift in the management of rare genetic disorders. At the forefront of this evolution stands the Hemophilia Therapeutics Market. This ...
Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...
Barbara Moran (67) from Co Mayo has cared for more than 600 patients since joining the Irish Cancer Society’s night nursing service in 2020, she shares her story Night nurse Barbara Moran says it is ...
Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
Scholar Rock plans to resubmit its application seeking approval for apitegromab, an investigational muscle-strengthening therapy for SMA.
Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...